On Wednesday, Shares of Chevron Corporation (NYSE:CVX), subtract -0.86% and closed at $102.15 in the last trading session. The last trading range of the stock ranges between $101.60 and $102.83. The company’s Market capitalization is $190.97 Billion with the total Outstanding Shares of 1.89 million. During the 52-week trading session the minimum price at which share price traded, registered at $75.33 and reached to max level of $107.58. Chevron U.S.A. Inc. ( NYSE : CVX ) declared recently the launch of its aFANity™ Rewards Program, a sports-themed rewards program available to residents of Alabama, Arizona, California, Florida, Georgia, Idaho, Louisiana, Mississippi, Nevada, New Mexico, Oregon, Tennessee, Texas, Utah, Washington and Wyoming. Eligible participants can sign up as members to begin earning points starting on October 1. They can redeem those points for prizes such as football tickets, autographed memorabilia, officially licensed team gear, and unique once-in-a-lifetime experiences with their favorite teams.
Sports fans will have a chance to reward themselves with exciting gear and memorabilia that fit their passion. Members earn points just for signing up with aFANity™ and can earn additional points through activities, like connecting their social media accounts, connecting their Chevron and Texaco Techron Advantage™ Credit Card, using their connected card at Chevron and Texaco stations in the participating areas, and even attending Chevron-sponsored football games.
BB&T Corporation (NYSE:BBT), dropped -0.10% and closed at $38.71 in the last trading session. The last trading range of the stock ranges between $38.66 and $39.00. The company’s Market capitalization is $31.18 Billion with the total Outstanding Shares of 814.50 million. During the 52-week trading session the minimum price at which share price traded, registered at $29.95 and reached to max level of $39.47. BB&T Corporation (BBT) recently declared it is contributing $1 million to the relief effort related to destruction and damage caused by Hurricane Matthew. BB&T is also delivering several truckloads of bottled water and cleaning supplies to affected communities in Central and Eastern North Carolina counting Fayetteville, Goldsboro, Greenville, Lumberton, and Wilson.
“We’re grateful our associates are safe and accounted for. But we also understand the need is still great in so many of the communities we serve,” said Chairman and Chief Executive Officer Kelly S. King. “Our thoughts and prayers are with all who are struggling to recover from Hurricane Matthew and we are hopeful this donation will assist them get back on their feet soon.”
To assist clients in their time of need, BB&T is diligently working to provide ATM service in affected areas. Clients who may have incurred storm-related overdraft, returned item, negative account balance or late loan payment fees are encouraged to visit one of our financial centers or contact BB&T at 800-BANK-BBT (800-226-5228) for assistance.
AstraZeneca plc (ADR)(NYSE:AZN), lost -1.03% and closed at $30.80 in the last trading session. The last trading range of the stock ranges between $30.68 and $31.08. During the 52-week trading session the minimum price at which share price traded, registered at $26.97 and reached to max level of $35.04. AstraZeneca recently declared data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg contrast to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.1 The primary endpoint was PFS and the FALCON trial enrolled 462 patients.
The results, declared at the 2016 European Society for Medical Oncology (ESMO) Congress, show that the median PFS was 2.8 months longer with fulvestrant than anastrozole (Hazard ratio 0.797; 95% confidence interval: 0.637-0.999; p=0.0486). The median PFS was 16.6 months in the fulvestrant arm, contrast with 13.8 months in the anastrozole arm.1 Aromatase inhibitors, such as anastrozole, are the current standard of care in 1st line treatment for postmenopausal women with hormone-receptor positive (HR+) advanced breast cancer.